BACKGROUND: Although gamma delta T cells are a major component of the human intestinal mucosa, it is not clear what role they play in mucosal immunity or if they are involved in the disease process of inflammatory bowel disease (IBD). MATERIALS AND METHODS: Flow cytometry and reverse transcriptase-polymerase chain reaction (RT-PCR) assays were used to identify quantitative and qualitative changes in the repertoire of gamma delta T cells present in surgical and/or biopsy samples or normal and inflamed colon from individual patients with ulcerative colitis (UC) or Crohn's disease (CD). Cytokine production and the ability to adhere to and interact with colonic fibroblasts were used to compare the functional properties of gamma delta T cells isolated from the normal and diseased colonic mucosa. RESULTS: Increased numbers of gamma delta T cells localized in areas of inflammation and tissue injury were found in the majority of patients, irrespective of the type of IBD present. This expansion was attributable to an increase in V delta 1+ cells expressing a V delta 1-(D delta 3)-J delta 1-encoded T cell receptor and was seen in patients with severe disease as well as those with newly diagnosed or less severe forms of IBD. Among T cells present in the inflamed mucosa of patients with CD, gamma delta T cells, particularly V delta 1+ cells, were a major source of the proinflammatory cytokine interferon-gamma and could interact with colonic fibroblasts. CONCLUSIONS: Our results demonstrate that the chronic inflammatory immune response characteristic of IBD is associated with distinct changes in the number, distribution, composition, and function of mucosal gamma delta T cells. Through the production of cytokines and physical interaction with other cells, gamma delta T cells can perform an immunoregulatory function and contribute to the pathophysiology of IBDs.
BACKGROUND: Although gamma delta T cells are a major component of the human intestinal mucosa, it is not clear what role they play in mucosal immunity or if they are involved in the disease process of inflammatory bowel disease (IBD). MATERIALS AND METHODS: Flow cytometry and reverse transcriptase-polymerase chain reaction (RT-PCR) assays were used to identify quantitative and qualitative changes in the repertoire of gamma delta T cells present in surgical and/or biopsy samples or normal and inflamed colon from individual patients with ulcerative colitis (UC) or Crohn's disease (CD). Cytokine production and the ability to adhere to and interact with colonic fibroblasts were used to compare the functional properties of gamma delta T cells isolated from the normal and diseased colonic mucosa. RESULTS: Increased numbers of gamma delta T cells localized in areas of inflammation and tissue injury were found in the majority of patients, irrespective of the type of IBD present. This expansion was attributable to an increase in V delta 1+ cells expressing a V delta 1-(D delta 3)-J delta 1-encoded T cell receptor and was seen in patients with severe disease as well as those with newly diagnosed or less severe forms of IBD. Among T cells present in the inflamed mucosa of patients with CD, gamma delta T cells, particularly V delta 1+ cells, were a major source of the proinflammatory cytokine interferon-gamma and could interact with colonic fibroblasts. CONCLUSIONS: Our results demonstrate that the chronic inflammatory immune response characteristic of IBD is associated with distinct changes in the number, distribution, composition, and function of mucosal gamma delta T cells. Through the production of cytokines and physical interaction with other cells, gamma delta T cells can perform an immunoregulatory function and contribute to the pathophysiology of IBDs.
Authors: M D Smith; B Bröker; L Moretta; E Ciccone; C E Grossi; J C Edwards; F Yüksel; B Colaco; C Worman; L Mackenzie Journal: Scand J Immunol Date: 1990-12 Impact factor: 3.487
Authors: J Kjeldsen-Kragh; A Quayle; C Kalvenes; O Førre; D Sørskaar; O Vinje; J Thoen; J B Natvig Journal: Scand J Immunol Date: 1990-12 Impact factor: 3.487
Authors: K Söderström; E Halapi; E Nilsson; A Grönberg; J van Embden; L Klareskog; R Kiessling Journal: Scand J Immunol Date: 1990-11 Impact factor: 3.487
Authors: Monali Manohar; Mark I Hirsh; Yu Chen; Tobias Woehrle; Anjali A Karande; Wolfgang G Junger Journal: J Leukoc Biol Date: 2012-06-29 Impact factor: 4.962
Authors: Madeleine D Hu; Alexander D Ethridge; Rebecca Lipstein; Sushil Kumar; Yitang Wang; Bana Jabri; Jerrold R Turner; Karen L Edelblum Journal: J Immunol Date: 2018-06-08 Impact factor: 5.422
Authors: E R Mann; N E McCarthy; S T C Peake; A N Milestone; H O Al-Hassi; D Bernardo; C T Tee; J Landy; M C Pitcher; S A Cochrane; A L Hart; A J Stagg; S C Knight Journal: Clin Exp Immunol Date: 2012-11 Impact factor: 4.330